Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 · View financials
Decision snapshot: SRPT stock price vs ENTG: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ENTG's multiple
Needs ENTG P/S.
Implied fair value · at SRPT's multiple
Needs SRPT P/S.
Metric by metric
Price unavailable
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: SRPT FY 2025 (ended Dec 31, 2025) · ENTG FY 2025 (ended Dec 31, 2025).
Trendline
Five fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Price framework
Discounted free cash flow, then bridged to a per-share price. Same assumptions applied to both companies.
SAREPTA THERAPEUTICS, INC. · implied price per share
Bear
-$43.23
Base
-$50.86
Bull
-$58.48
Entegris, Inc. · implied price per share
Bear
$29.61
Base
$34.83
Bull
$40.06
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.82x
0.97x
Net debt / EBITDA
Leverage against operating earnings
0.01x
3.27x
Cash and equivalents
Liquid reserves on the balance sheet
$939.65M
$362.58M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMGEN INC
SRPT vs AMGN
BIOMARIN PHARMACEUTICAL INC
SRPT vs BMRN
Replimune Group, Inc.
SRPT vs REPL
PTC THERAPEUTICS, INC.
SRPT vs PTCT
DuPont de Nemours, Inc.
SRPT vs DD
APPLIED MATERIALS INC /DE
SRPT vs AMAT
LAM RESEARCH CORP
SRPT vs LRCX
ASML HOLDING NV
SRPT vs ASML
MKS INSTRUMENTS INC
SRPT vs MKSI
$934.46M
$3.85B
Live quote
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
Based on an earlier data snapshot. Review the filing dates below or refresh after signing in.
If you believe SRPT can convert its 15.6% revenue growth into durable positive margins and avoid distress, then the current price could be attractive because the stock trades at only 0.9x P/S versus ENTG's 6.9x; otherwise, the low multiple is justified by SRPT's negative profitability and weak quality scores.
On a P/S basis, SRPT at 0.9x versus ENTG at 6.9x implies a large valuation gap and the provided implied price of $144.08 suggests 647.3% upside from the current $19.28. However, the gap is not unexplained: SRPT has negative margins and negative earnings while ENTG is profitable with positive operating and net margins.
Supporting Metrics
Price unavailable
